
Encompass Health Corporation: updates and filings
Price
$134.93
November 18, 2026Market cap $13.4B
What Ploutos Investor adds for Encompass Health
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 28, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 6, 2026Regulation FD disclosureForm8-K
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 28, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 19, 2026Shelf registration for future offeringsFormS-3ASR
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Other material eventsForm8-K
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 1, 2026Material agreement entered, new material financial obligationForm8-K
- May 15, 2026Material agreement entered, other material eventsForm8-K
- May 11, 2026Shareholder voteForm8-K
- May 1, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 7, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 7, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 10, 2026Material agreement entered, material agreement ended, new material financial obligationForm8-K
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 20, 2026Officer or director change (amendment)Form8-K/A
- Feb 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 2, 2026Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 6, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 28, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 19, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | 8-K | Other material events | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 1, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| May 15, 2026 | 8-K | Material agreement entered, other material events | Document |
| May 11, 2026 | 8-K | Shareholder vote | Document |
| May 1, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 7, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 7, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 10, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 20, 2026 | 8-K/A | Officer or director change (amendment) | Document |
| Feb 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 2, 2026 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 10, 1994. Of its note and share prospectuses (424B, FWP), the newest 40 of 87.
The full analysis
What do Encompass Health's filings show?
The filings are where every one of Encompass Health's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.